ACG Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

ACG Wealth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-75	Closed	-$6K	–	1025
2022 Q2	$6K	Buy	+75	New	+$5.63K	﹤0.01%	757
2021 Q1	–	Sell	-1,617	Closed	-$228K	–	349
2020 Q4	$228K	Buy	+1,617	New	+$207K	0.03%	275
2018 Q4	–	Sell	-2,092	Closed	-$201K	–	337
2018 Q3	$201K	Buy	+2,092	New	+$203K	0.03%	297

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ACG Wealth's XBI Position: Q3 2022 in Review

ACG Wealth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 75 shares — an estimated $6K sold.

ACG Wealth first reported a position in XBI in Q3 2018 and held it in 3 quarters. The position peaked at $228K in Q4 2020. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

ACG Wealth reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 75 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $6K.
ACG Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and held it in 3 quarters.
ACG Wealth's State Street SPDR S&P Biotech ETF position peaked at $228K in Q4 2020.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.